TegoScience Inc - Asset Resilience Ratio

Latest as of March 2026: 51.30%

TegoScience Inc (191420) has an Asset Resilience Ratio of 51.30% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 191420 strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩38.50 Billion
≈ $26.09 Million USD Cash + Short-term Investments

Total Assets

₩75.05 Billion
≈ $50.86 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2025)

This chart shows how TegoScience Inc's Asset Resilience Ratio has changed over time. See net asset quality index of TegoScience Inc to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down TegoScience Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 191420 company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩38.50 Billion 51.3%
Total Liquid Assets ₩38.50 Billion 51.30%

Asset Resilience Insights

  • Very High Liquidity: TegoScience Inc maintains exceptional liquid asset reserves at 51.30% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

TegoScience Inc Industry Peers by Asset Resilience Ratio

Compare TegoScience Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
Pharmaceuticals 4.82%
ST Pharm Co.Ltd
KQ:237690
Pharmaceuticals 7.72%
NatureCell Co.Ltd
KQ:007390
Pharmaceuticals 0.00%
Oscotec Inc
KQ:039200
Pharmaceuticals 65.38%
Caregen Co.Ltd
KQ:214370
Pharmaceuticals 4.58%
Kolon Life Science Inc
KQ:102940
Pharmaceuticals 1.22%
Mezzion Pharma Co.Ltd
KQ:140410
Pharmaceuticals 13.09%
Komipharm International Co. Ltd
KQ:041960
Pharmaceuticals 0.00%

Annual Asset Resilience Ratio for TegoScience Inc (2015–2025)

The table below shows the annual Asset Resilience Ratio data for TegoScience Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 49.64% ₩38.80 Billion
≈ $26.29 Million
₩78.16 Billion
≈ $52.97 Million
-2.42pp
2024-12-31 52.06% ₩27.34 Billion
≈ $18.53 Million
₩52.52 Billion
≈ $35.59 Million
+9.30pp
2023-12-31 42.76% ₩20.91 Billion
≈ $14.17 Million
₩48.91 Billion
≈ $33.15 Million
-0.67pp
2022-12-31 43.43% ₩22.31 Billion
≈ $15.12 Million
₩51.36 Billion
≈ $34.81 Million
+1.65pp
2021-12-31 41.78% ₩21.31 Billion
≈ $14.44 Million
₩51.00 Billion
≈ $34.56 Million
-3.79pp
2020-12-31 45.58% ₩22.97 Billion
≈ $15.57 Million
₩50.40 Billion
≈ $34.16 Million
-0.32pp
2019-12-31 45.90% ₩22.29 Billion
≈ $15.11 Million
₩48.57 Billion
≈ $32.91 Million
+22.22pp
2018-12-31 23.67% ₩11.26 Billion
≈ $7.63 Million
₩47.56 Billion
≈ $32.23 Million
+1.76pp
2017-12-31 21.92% ₩10.43 Billion
≈ $7.07 Million
₩47.59 Billion
≈ $32.25 Million
-23.31pp
2016-12-31 45.22% ₩20.19 Billion
≈ $13.68 Million
₩44.64 Billion
≈ $30.25 Million
+33.58pp
2015-12-31 11.65% ₩3.00 Billion
≈ $2.03 Million
₩25.76 Billion
≈ $17.46 Million
--
pp = percentage points

About TegoScience Inc

KQ:191420 Korea Pharmaceuticals
Market Cap
$40.93 Million
₩60.40 Billion KRW
Market Cap Rank
#22681 Global
#1460 in Korea
Share Price
₩7480.00
Change (1 day)
-5.20%
52-Week Range
₩7480.00 - ₩18970.00
All Time High
₩71600.00
About

TegoScience Inc. produces and sells wound-healing skin cell therapy products from human epithelial cells in South Korea. The company's products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services. The company was founded in 2001 and is based in Seoul, South Korea.